Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (281-290 of 410) with videos related to

Pageof 41
Sort By:
Neuro-Oncology|March 19, 2019
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymomaMark W Kieran, Liliana Goumnerova, Peter Manley, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Pediatric Blood & Cancer|May 26, 2017
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium studyMargaret E Macy, Mark W Kieran, Susan N Chi, et al.
Pediatric Blood & Cancer|May 12, 2018
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous systemPeter E Manley, Tanya Trippett, Amy A Smith, et al.
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
European Urology|January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate CancerKim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Pageof 41

Showing results (281-290 of 410) with videos related to

Sort By:
Pageof 41
Neuro-Oncology|March 19, 2019
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymomaMark W Kieran, Liliana Goumnerova, Peter Manley, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
Pediatric Blood & Cancer|May 26, 2017
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium studyMargaret E Macy, Mark W Kieran, Susan N Chi, et al.
Pediatric Blood & Cancer|May 12, 2018
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous systemPeter E Manley, Tanya Trippett, Amy A Smith, et al.
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.
Cancer Medicine|March 22, 2021
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncologyDavid S Shulman, Lulla V Kiwinda, Stacey Edwards, et al.
European Urology|January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate CancerKim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Pageof 41